CAS 941685-37-6
:Incb 18424
Description:
Incb 18424, with the CAS number 941685-37-6, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule and is known to exhibit properties that may influence biological pathways, making it a candidate for drug development. The compound's structure typically includes specific functional groups that contribute to its reactivity and interaction with biological targets. While detailed pharmacological data may vary, compounds like Incb 18424 are often evaluated for their efficacy, safety, and mechanism of action in preclinical and clinical studies. Additionally, its solubility, stability, and bioavailability are critical factors that determine its suitability for therapeutic use. As research progresses, further insights into its characteristics, including its pharmacokinetics and potential side effects, will be essential for understanding its role in medical applications.
Formula:C17H17N6
InChI:InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m0/s1
InChI key:InChIKey=HFNKQEVNSGCOJV-HNNXBMFYSA-N
SMILES:[C@@H](CC#N)(N1C=C(C2=C3C(=NC=N2)NC=C3)C=N1)C4CCCC4
Synonyms:- S-Ruxolitinib (INCB018424)
- CS-1401
- S-Ruxolitinib
- Ruxolitinib Impurity A
- Ruxolitinib Impurity 1（(S)-Ruxolitinib）
- (S)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
- RUXOLITINIB S ENANTIOMER;INCB18424
- (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
- (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (ent-Ruxolitinib)
- Ruxolitinib (S enantioMer)
- 1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-
- See more synonyms
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
(S)-Ruxolitinib
CAS:Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoiFormula:C17H18N6Color and Shape:Off-White SolidMolecular weight:306.15929Ruxolitinib (S enantiomer)
CAS:Ruxolitinib (S enantiomer)Formula:C17H18N6Purity:≥98%Molecular weight:306.36(S)-Ruxolitinib
CAS:Controlled ProductApplications (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile is a newly developed JAK2 inhibitor therapy aimed to improve MPN-associated splenomegaly and systemic symptoms. The opposite enantiomer of Ruxolitinib (R702000).
References Koppikar, P., et al.: Nature., 489, 155 (2012); Ratcliffe, A.J., et al.: Drug. Discover. Series., 19, 218 (2012);Formula:C17H18N6Color and Shape:NeatMolecular weight:306.36Ruxolitinib (S enantiomer)
CAS:Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.Formula:C17H18N6Purity:99.37% - 99.79%Color and Shape:SolidMolecular weight:306.365Ruxolitinib (S enantiomer)
CAS:(S)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileFormula:C17H18N6Purity:98%Molecular weight:306.37S-Ruxolitinib (INCB018424)
CAS:Ruxolitinib is a janus tyrosine kinase inhibitor active specifically on sub-types JAK1 and JAK2 with IC50 values in the nanomolar range. JAK1 and JAK2 are kinases involved in the regulation of hematopoiesis. Clinically applied to the treatment of intermediate and high-risk myelofibrosis, ruxolitinib is usually well tolerated by patients.Formula:C17H18N6Purity:Min. 95%Molecular weight:306.37 g/mol1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-
CAS:Formula:C17H18N6Purity:98%Color and Shape:SolidMolecular weight:306.3650
![1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-](https://static.cymitquimica.com/products/IN/thumb/DA000BIK.jpg)